Comparison of AstraZeneca and Sinopharm in protection against COVID-۱۹ infection

سال انتشار: 1401
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 132

فایل این مقاله در 6 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

SCCFSTS01_060

تاریخ نمایه سازی: 26 بهمن 1401

چکیده مقاله:

BackgroundAcute Respiratory Infections (ARIs) are the most prevalent diseases that affected individuals of all ages worldwide. Multiple viruses cause ARIs including coronaviruses. The global burden of the SARS-CoV-۲ pandemic evaluated about ۴۵ million confirmed cases including over ۶ million deaths. Studies showed that two doses of vaccination play an important role in decreasing hospitalization and mortality rate among patients but the efficacy of a booster dose is also important. We aimed to show which type of vaccine causes better immunity and fewer symptoms manifestation against Omicron as a booster dose.Methods:We conducted a cross-sectional study on individuals who were admitted to the hospital with respiratory symptoms. Possible SARS-CoV-۲ infection by using Real-time PCR was conducted and after that, We have limited the study to infected people with a history of ۳ doses of vaccination, injected ۲ doses of BIBP (Sinopharm) and a similar or different booster dose, BIBP or AZD۱۲۲۲ (AstraZeneca), and inquired them about their age, gender, type of injected vaccine for the third dose, and all respiratory symptoms of these patients were investigated.Results:Among ۳۴۶ cases, ۱۲۰ cases were positive for SARS-CoV-۲ but vaccinated with two doses of Sinopharm and a different booster doses of AZD۱۲۲۲ or BIBP were ۹۴ among these ۱۲۰ cases. patients vaccinated with AZD۱۲۲۲ as a booster dose showed fewer symptoms compared to those vaccinated with three doses of BIBP.Conclusions:As a result, the patients vaccinated with ۲ doses of BIBP and AZD۱۲۲۲ as a booster dose(n=۲۶) manifested mild symptoms to those who were vaccinated with ۳ doses of BIBP(n=۶۸). Therefore, ou study showed injecting a booster dose will help in decreasing hospitalization and severity of the infection, and also it seems that the third dose of vaccination with AZD۱۲۲۲ is better than BIBP and it is suggested to make better immunity against SARS-CoV-۲.

کلیدواژه ها:

نویسندگان

aArash Letafati

Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Mahdokht Younesi

Departmrnt of Genetics, School of Basic Sciences, Yazd University, Ghazvin, Iran

Simin Tavakolipasand

Department of Parasitology, School of Medicine, Shahrekord University of Medical Sciences